Topokine Therapeutics is a clinical-stage biotechnology company developing topical medicines that act on subcutaneous fat to contour the face and body without surgery or injections.

The company’s lead program, XAF5 Ointment, is a fat-reducing agent in late-stage development for undereye bags (steatoblepharon).  This condition affects over 90 million Americans and can make the face look fatigued, aged, or angry.

Topokine’s second clinical asset, TAT4 Gel, is in Phase 2 development as a topical “filler” to smooth nasolabial folds and facial wrinkles.